[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TNRC6C

Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF10427 Argonaute hook
PF12938 M domain of GW182
PF00076 RNA recognition motif. (a.k.a. RRM
PF16608 TNRC6-PABC binding domain
PF00627 UBA/TS-N domain
Function

Plays a role in RNA-mediated gene silencing by micro-RNAs (miRNAs). Required for miRNA-dependent translational repression of complementary mRNAs by argonaute family proteins. As scaffoldng protein associates with argonaute proteins bound to partially complementary mRNAs and simultaneously can recruit CCR4-NOT and PAN deadenylase complexes.

> Gene Ontology
 
Biological Process GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006417 regulation of translation
GO:0007223 Wnt signaling pathway, calcium modulating pathway
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010608 posttranscriptional regulation of gene expression
GO:0016055 Wnt signaling pathway
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0017148 negative regulation of translation
GO:0019439 aromatic compound catabolic process
GO:0031047 gene silencing by RNA
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0035194 posttranscriptional gene silencing by RNA
GO:0035195 gene silencing by miRNA
GO:0035278 miRNA mediated inhibition of translation
GO:0035567 non-canonical Wnt signaling pathway
GO:0040029 regulation of gene expression, epigenetic
GO:0040033 negative regulation of translation, ncRNA-mediated
GO:0044270 cellular nitrogen compound catabolic process
GO:0045974 regulation of translation, ncRNA-mediated
GO:0046700 heterocycle catabolic process
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0060211 regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0060213 positive regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0061013 regulation of mRNA catabolic process
GO:0061014 positive regulation of mRNA catabolic process
GO:0198738 cell-cell signaling by wnt
GO:1900151 regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1900153 positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1901361 organic cyclic compound catabolic process
GO:1903311 regulation of mRNA metabolic process
GO:1903313 positive regulation of mRNA metabolic process
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4086398: Ca2+ pathway
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-74160: Gene Expression
R-HSA-211000: Gene Silencing by RNA
R-HSA-212436: Generic Transcription Pathway
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-198203: PI3K/AKT activation
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-426496: Post-transcriptional silencing by small RNAs
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912408: Pre-NOTCH Transcription and Translation
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-157118: Signaling by NOTCH
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-195721: Signaling by Wnt
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNRC6C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNRC6C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNRC6C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0960.69
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1040.901
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.090.89
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1120.676
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.040.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3050.923
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3880.17
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.450.718
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2640.857
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3290.596
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9490.24
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0270.788
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNRC6C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNRC6C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNRC6C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNRC6C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNRC6C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNRC6C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNRC6C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNRC6C
Nametrinucleotide repeat containing 6C
Aliases KIAA1582; FLJ20015; Trinucleotide repeat-containing gene 6C protein
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNRC6C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.